 |
|
Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy
Daniel A. Sussman, MD;
Erika Escalona-Benz, MD;
Matthew S. Benz, MD;
Brandy C. Hayden, BS;
William Feuer, MS;
Nicole Cicciarelli;
Stuart Toledano, MD;
Arnold Markoe, MD;
Timothy G. Murray, MD
Arch Ophthalmol. 2003;121:979-984.
Objective To determine the time course and extent of tumor reduction associated with systemic chemotherapy or external beam radiotherapy (EBRT) in the treatment of advanced intraocular retinoblastoma.
Methods Retrospective review of children with ReeseEllsworth stages IV and V retinoblastoma undergoing primary globe-conserving therapy with either systemic chemoreduction or EBRT. Study variables were recorded at baseline, at monthly intervals for the first 6 months, and at 12 months after the initiation of treatment. Tumor volumes were calculated using basal area and height values determined by ultrasonography, physical examination, and fundus photographic review.
Main Outcome Measures Outcome measures included tumor volume, tumor reduction, regression pattern, treatment-related complications, metastases, and survival.
Results Twenty-six eyes of 26 patients were evaluated for tumor response; 18 patients were treated with systemic chemotherapy and 8 patients were treated with EBRT. Median follow-up was 36 months. A mean 68% reduction in tumor volume occurred after 1 cycle of chemotherapy compared with a 12% reduction at a similar time point (1 month) after initiation of EBRT (P<.004). There was no statistically significant difference in tumor volume reduction between treatment modalities at the 12-month follow-up visit. Both systemic chemoreduction and EBRT achieved 100% globe conservation and 100% patient survival in this series.
Conclusions Retinoblastoma reduction exhibits a differential time course based on the applied primary treatment. Systemic chemotherapy is associated with earlier tumor reduction than EBRT.
From the Bascom Palmer Eye Institute (Drs Sussman, Escalona-Benz, Benz, and Murray, Mss Hayden and Cicciarelli, and Mr Feuer), and the Divisions of Pediatric Hematology and Oncology (Dr Toledano) and Radiation Oncology (Dr Markoe), University of Miami School of Medicine, Miami, Fla. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Systemic carboplatin for retinoblastoma: change in tumour size over time
Abramson et al.
Br. J. Ophthalmol. 2005;89:1616-1619.
ABSTRACT
| FULL TEXT
Outcome Following Initial External Beam Radiotherapy in Patients With Reese-Ellsworth Group Vb Retinoblastoma
Abramson et al.
Arch Ophthalmol 2004;122:1316-1323.
ABSTRACT
| FULL TEXT
|
